ArticleACS nano medicine2026
Precision Temperature Control of Volume Phase Transition in Biocompatible PEG-Based Nanogels for Triggered Drug Release.
Article in ACS nano medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thermoresponsive nanogels (NGs) can reversibly alter their structure in response to temperature changes. This enables controlled drug release, targeted therapy, and improved treatment precision under physiological or externally applied thermal conditions. Despite these advantages, few studies have systematically tuned the volume phase transition temperature (VPTT) of oligo-(ethylene glycol) methacrylates (OEGMA)-based NGs across physiologically relevant temperatures while maintaining stability and biodegradability. In this work, NGs were synthesized using di-(ethylene glycol) methyl ether methacrylate (DEGMA), tri-(ethylene glycol) methyl ether methacrylate (TEGMA), and 2-methoxyethyl methacrylate (MOEMA) monomers, achieving finely tuned VPTT with a precision within 1 °C. The NGs exhibited diameters ranging from 200 to 350 nm and a negative ζ-potential. Upon reaching the VPTT, the NGs shrank to sizes below 100 nm while becoming monodisperse. Specifically, NG@TEGMA exhibited VPTT between 50-60 °C, NG@DEGMA between 30-45 °C, and NG@TEGMA_DEGMA between 64-66 °C, and NG@TEGMA_MOEMA with molar ratios of 40%, 30%, and 20% displayed VPTT of 37, 47, and 52 °C, respectively. NG@TEGMA NGs were further polymerized with a methacrylated docetaxel derivative, achieving an encapsulation efficiency of 93 ± 4%. These NGs released approximately 90% of the drug upon reaching the VPTT, while nonthermoresponsive controls only released about 20% of the drug. Furthermore, NG@TEGMA demonstrated negligible cytotoxicity and efficient cellular uptake. This study demonstrates a biocompatible and degradable platform of OEGMA-based thermoresponsive NGs for biomedical applications such as hyperthermia-driven drug delivery for cancer therapy with superior thermoresponsive behavior to previously reported OEGMAs-, NIPAM-, or VCL-based NGs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.